BioSpace News Archive

Celmatix announced that Richard Hofbauer has joined its executive team in the role of Chief Operating Officer (COO) and interim Chief Financial Officer (CFO).

Trientine hydrochloride is used in the treatment of patients with Wilson’s disease who are intolerant of penicillamine.

The studies show that degradation of the androgen receptor with ARV-110 leads to inhibition of AR target gene expression and the proliferation of prostate cancer cell lines.

Decibel scientists have been selected to present four posters and deliver two podium presentations at the 41st Annual ARO Midwinter Meeting in San Diego, Calif.

This ruling ends the challenge brought by Koios Pharmaceuticals LLC.

Revenues for the year ended December 31, 2017 were $115.4 million, compared to $48.6 million for the year ended December 31, 2016.

Of these notes, $500 million will mature in 2021 and will bear interest at an annual rate of 2.875 percent, $1.0 billion will mature in 2023 and will bear interest at an annual rate of 3.25 percent, $1.5 billion will mature in 2028 and will bear interest at an annual rate of 3.90 percent and $1.5 billion will mature in 2048 and will bear interest at an annual rate of 4.55 percent.

As part of this partnership, Emmaus will leverage the breadth of AmerisourceBergen’s integrated commercialization solutions to support adherence and realize the best possible outcomes for patients.

Series B funds will be used to complete two ongoing U.S. pivotal clinical trials of the Simplify Disc studying its use in one level of the spine and in two adjacent levels of the spine as a treatment for cervical degenerative disc disease, and for commercialization outside of the U.S.

Dr. Edgar joins the Cogstate team in Europe as an experienced leader in cognitive assessment and clinical endpoint strategy.